Morgan Stanley lowered the firm’s price target on NeoGenomics (NEO) to $10 from $17 and keeps an Equal Weight rating on the shares. The company’s Q1 miss was primarily driven by lower non-clinical revenue and lower than expected average unit price, says the analyst, who sees “more questions than answers” following the company’s quarterly report.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEO:
- NeoGenomics price target lowered to $12 from $17 at TD Cowen
- NeoGenomics price target lowered to $10 from $12 at BofA
- NeoGenomics price target lowered to $12 from $17 at BTIG
- NeoGenomics: Hold Rating Amid Mixed Financial Performance and Market Conditions
- NeoGenomics Reports Strong Q1 2025 Performance
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue